Awarded points for VTS prognostic score

	0 points	0.5 points	1 point
Cumulative brain metastases volume	>1.5 cc	<1.5 cc
Timing of metastasis	Synchronous	Metachronous
Systemic treatment	Targeted therapy		Immunotherapy
Survival of patients grouped by the VTS score
VTS score	n = 110	Median OS (months)
0-1	46	5.1
1.5	36	18.9
2	28	34.5

The VTS prognostic score incorporates the influence of cumulative brain metastasis volume, timing of metastases, and choice of systemic treatment (immunotherapy or targeted therapy). Median OS can be predicted based on the cumulative VTS score.

VTS: volume-timing-systemic therapy; OS: overall survival.

Adapted from: Schaule J, Kroeze SGC, Blanck O, et al. Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy: Melanoma brain metastases prognostic score. Radiat Oncol 2020; 15:135. Copyright © 2020 The Authors. Available at: https://ro-journal.biomedcentral.com/articles/10.1186/s13014-020-01558-8 (Accessed on July 22, 2021). Reproduced under the terms of the Creative Commons Attribution 4.0 License.

Graphic 132097 Version 1.0

خرید پکیج

Awarded points for VTS prognostic score